VCIM
BOLT icon

Velan Capital Investment Management’s Bolt Biotherapeutics BOLT Stock Holding History

Velan Capital Investment Management’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,500
Closed -$26.8K – 48
2024
Q4 		$26.8K Buy
+2,500
New +$30.2K 0.02% 42
2023
Q2 		– Sell
-7,000
Closed -$195K – 32
2023
Q1 		$195K Buy
+7,000
New +$205K 0.17% 31

Other funds holding BOLT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Velan Capital Investment Management's BOLT Position: Q1 2025 in Review

Velan Capital Investment Management sold out of Bolt Biotherapeutics (BOLT) in Q1 2025, closing a stake of 2,500 shares — an estimated $26.8K sold.

Velan Capital Investment Management first reported a position in BOLT in Q1 2023 and held it in 2 quarters. The position peaked at $195K in Q1 2023. 29 funds tracked by Wall St. Rank hold BOLT as of Q1 2025.

  • Velan Capital Investment Management reported no remaining Bolt Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Velan Capital Investment Management sold 2,500 Bolt Biotherapeutics shares in Q1 2025, an estimated $26.8K.
  • Velan Capital Investment Management first reported a position in Bolt Biotherapeutics in Q1 2023 and held it in 2 quarters.
  • Velan Capital Investment Management's Bolt Biotherapeutics position peaked at $195K in Q1 2023.
  • 29 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2025.

Based on Velan Capital Investment Management's 13F filing for Q1 2025, filed 15 May 2025.